NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.
相关临床试验
8
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
3
37.5%
招募中
2
25.0%
终止
2
25.0%
撤回
1
12.5%
暂无批准数据
- NKGen Biotech reported encouraging Phase 1 results for troculeucel, an autologous NK cell therapy, showing 100% of moderate Alzheimer's disease patients achieved cognitive stability or improvement at three-month assessment. - Higher cell doses (4-6 billion cells) demonstrated greater directional cognitive improvement and more frequent achievement of clinically meaningful change thresholds across standardized measures. - Plasma GFAP emerged as a potential non-invasive biomarker, showing strong correlations with cognitive status that strengthened in patients receiving higher troculeucel doses. - The therapy maintained a favorable safety profile with no treatment-related adverse events reported across both Phase 1 studies.
- NKGen Biotech will present preliminary clinical and biomarker results for troculeucel, an investigational autologous enhanced NK cell therapy for moderate to advanced Alzheimer's disease, at the XXVII World Congress of Neurology in Seoul. - The company's CEO Dr. Paul Y. Song will also present the latest clinical data supporting troculeucel's use in neurodegenerative diseases at the 3rd China Great Bay Cell and Gene Therapy Forum in Guangzhou. - Troculeucel represents a novel cell-based, patient-specific immunotherapeutic approach that has received WHO International Nonproprietary Name approval, marking a significant regulatory milestone. - The presentations underscore NKGen's commitment to advancing NK cell-based approaches for neurodegenerative disorders and contributing to the future of Alzheimer's treatment.
- NKGen Biotech acquired a 65% equity stake in Korean biotech company NKMax for $16.9 million, gaining full control of global manufacturing infrastructure and intellectual property assets. - The acquisition transforms NKGen into a vertically integrated NK cell therapy company with enhanced capabilities to advance its lead Alzheimer's treatment, troculeucel. - Troculeucel has received FDA fast track designation and demonstrates cessation of disease progression or cognitive improvements in over 90% of Alzheimer's patients treated to date. - The transaction was funded by AlpineBrook Capital GP 1 Limited and CEO Dr. Paul Y. Song, with NKMax operations now funded through 2026.
- NKGen Biotech CEO Paul Song has invested $2.65 million of his personal funds to accelerate the company's phase 2 Alzheimer's disease cell therapy trial amid significant financial challenges. - The California-based biotech ended September with only $8,000 in cash and a $177 million deficit, making Song's investment crucial for trial advancement and meeting public company obligations. - NKGen's investigational therapy SNK01 uses patients' own natural killer cells that are expanded and activated outside the body before readministration, with the phase 1/2a study in moderate Alzheimer's patients having begun in 2023.
- The NK cell therapy market is experiencing robust growth driven by increasing interest in immuno-oncology and advancements in cell engineering technologies, with significant expansion expected through 2034. - Leading companies including Artiva Biotherapeutics, Glycostem, Fate Therapeutics, and Senti Biosciences are developing promising therapies such as AlloNK, oNKord, and FT522, with several receiving FDA designations for expedited development. - Off-the-shelf NK cell therapies are emerging as a key trend, offering advantages in manufacturing scalability, immediate availability, and potential applications beyond oncology into autoimmune diseases.
- NKGen Biotech's innovative NK cell therapy troculeucel has received FDA Fast Track Designation for treating moderate Alzheimer's disease, potentially accelerating its development pathway. - Early clinical benefits were observed in Phase 1 trials of troculeucel, an ex vivo expanded autologous NK cell therapy, showing promise for moderate Alzheimer's patients. - The company is currently conducting Phase 2a trials, with updated clinical data expected by the end of 2025, addressing a critical need in the 30% of Alzheimer's cases classified as moderate.
• Over 120 Alzheimer's Disease treatment therapies are under development by 110+ companies globally, ranging from preclinical to marketed phases. • Emerging therapies like NRDN-201, ST-501, and KarXT are in various clinical trial phases, showing potential for significant market impact. • MapLight Therapeutics initiated a Phase 1 trial for ML-007/PAC, targeting schizophrenia and Alzheimer's disease psychosis, with Phase 2 trials planned. • The FDA granted conventional approval to Leqembi (lecanemab-irmb), marking the first amyloid beta-directed antibody to transition from accelerated approval.
- Lexeo Therapeutics' LX1001 gene therapy shows dose-dependent APOE2 expression increase and reduced tau biomarkers in APOE4 homozygote Alzheimer's patients. - Lomecel-B cell therapy demonstrates safety and potential cognitive benefits in mild Alzheimer's patients, according to Phase 2a CLEAR MIND trial data. - NKGen Biotech advances SNK01 natural killer cell therapy to Phase 2 after promising Phase 1 results, including cognitive function improvements. - Regeneration Biomedical doses first patient in Phase 1 trial of RB-ADSC, an autologous stem cell therapy for Alzheimer's, showing no adverse events.
- NKGen Biotech's troculeucel demonstrated a reduction in key Alzheimer's disease biomarkers, including GFAP and p-tau181, suggesting potential for early intervention. - In a Phase 1/2a trial, the highest dose of troculeucel (6 billion cells) showed no adverse reactions and cognitive function was stable or improved in all subjects. - Two out of three moderate Alzheimer's patients treated with troculeucel experienced a notable improvement to mild cognitive impairment after three months. - These findings support further investigation of troculeucel as a potential therapy to delay or prevent dementia onset, warranting further randomized, placebo-controlled Phase 2a study.
- Acumen Pharmaceuticals will present data on using plasma pTau217 assay for screening participants in their Phase 2 ALTITUDE-AD trial. - The ALTITUDE-AD trial is evaluating sabirnetug (ACU193) for early Alzheimer's, targeting soluble amyloid beta oligomers. - NKGen Biotech will present posters on Phase 1 and Phase 1/2a studies of troculeucel in Alzheimer's patients at the CTAD conference. - Troculeucel, an autologous natural killer cell therapy, is being developed for neurodegenerative disorders and cancers by NKGen.
